ReviewLeukemia2009
Chronic myeloproliferative diseases with and without the Ph chromosome: some unresolved issues.
Review in Leukemia, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 30 citations in OpenAlex.
- Identification of the MRTFA/SRF pathway as a critical regulator of quiescence and chemotherapy resistance in cancer.Cancer letters · 2026Article
- Bilateral testicular infiltration as the initial presentation of NRAS-mutant juvenile myelomonocytic leukemia: rapid molecular remission following azacitidine and haploidentical stem cell transplantation.Leukemia research reports · 2026Article
- Article
- The cancer stem cell niche: how essential is the niche in regulating stemness of tumor cells?Cell stem cell · 2015Review
- Successful transplantation of ethnically mismatched cord blood in a boy with atypical chronic myeloid leukemia.International journal of hematology · 2013Article
- The evolving concept of cancer and metastasis stem cells.The Journal of cell biology · 2012Review
- Dual inhibition of Jak2 and STAT5 enhances killing of myeloproliferative neoplasia cells.Leukemia · 2012Article
- Absence of JAK2V617F mutation in patients with beta-thalassemia major and thrombocytosis due to splenectomy.Molecular biology reports · 2012Article
- ΔNp63α promotes cellular quiescence via induction and activation of Notch3.Cell cycle (Georgetown, Tex.) · 2011Article
- Stem cell quiescence.Clinical cancer research : an official journal of the American Association for Cancer Research · 2011Review
- LIF, a Novel STAT5-Regulated Gene, Is Aberrantly Expressed in Myeloproliferative Neoplasms.Genes & cancer · 2011Article
- The cancer stem cell: premises, promises and challenges.Nature medicine · 2011Review
- JAK2 Allele Burden in the Myeloproliferative Neoplasms: Effects on Phenotype, Prognosis and Change with Treatment.Therapeutic advances in hematology · 2011Article
- Targeting leukemic stem cells by breaking their dormancy.Molecular oncology · 2010Review
- Review
- Aurora kinase inhibitors: novel small molecules with promising activity in acute myeloid and Philadelphia-positive leukemias.Leukemia · 2010Review
- Awakening dormant haematopoietic stem cells.Nature reviews. Immunology · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 9 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ph-positive chronic myeloid leukemia (CML) and Ph-negative chronic myeloproliferative diseases (MPDs), characterized in many cases by the presence of the JAK2(V617F) mutation, have many features in common and yet also show fundamental differences. In this review, we pose five discrete and related questions relevant to both categories of hematological malignancy, namely: What are the mechanisms that underlie disease progression from a relatively benign or chronic phase? By what therapeutic methods might one target residual leukemia stem cells in CML? Is JAK2(V617F) the original molecular event in MPD? What epigenetic events must have a role in dictating disease phenotype in MPDs? And finally, Will the benefits conferred by current or future JAK2(V617F) inhibitors equal or even surpass the clinical success that has resulted from the use of tyrosine kinase inhibitors in CML? These and others questions must be addressed and in some cases should be answered in the foreseeable future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.